1. Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study.
- Author
-
Pikis, Stylianos, Mantziaris, Georgios, Protopapa, Maria, Tos, Salem, Kowalchuk, Roman, Ross, Richard, Rusthoven, Chad, Tripathi, Manjul, Langlois, Anne-Marie, Mathieu, David, Lee, Cheng-Chia, Yang, Huai-Che, Peker, Selcuk, Samanci, Yavuz, Zhang, Michael, Braunstein, Steve, Wei, Zhishuo, Niranjan, Ajay, Lunsford, Dade, and Sheehan, Jason
- Subjects
Brain metastasis ,Breast cancer ,Gamma Knife ,Radiosurgery ,Humans ,Female ,Breast Neoplasms ,Radiosurgery ,Middle Aged ,Brain Neoplasms ,Retrospective Studies ,Receptor ,ErbB-2 ,Aged ,Prognosis ,Treatment Outcome ,Follow-Up Studies ,Adult - Abstract
PURPOSE: To report patient outcomes and local tumor control rates in a cohort of patients with biopsy-proven HER-2 positive breast cancer treated with stereotactic radiosurgery (SRS) for brain metastases (BM). METHODS: This international, retrospective, multicenter study, included 195 female patients with 1706 SRS-treated BM. Radiologic and clinical outcomes after SRS were determined and prognostic factors identified. RESULTS: At SRS, median patient age was 55 years [interquartile range (IQR) 47.6-62.0], and 156 (80%) patients had KPS ≥ 80. The median tumor volume was 0.1 cm3 (IQR 0.1-0.5) and the median prescription dose was 16 Gy (IQR 16-18). Local tumor control (LTC) rate was 98%, 94%, 93%, 90%, and 88% at six-, 12-, 24-, 36- and 60-months post-SRS, respectively. On multivariate analysis, tumor volume (p =
- Published
- 2024